We conducted a multisite, phase 1b, open-label study of the first-generation EGFR TKI erlotinib in combination with JAK1/2 and TBK1 inhibitor momelotinib in 11 patients with EGFR TKI-treatment–naive EGFR-mutated advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.